METHODS: This review summarised the findings of 15 articles. The articles were experimental, compared intervention with a control group, published between 2012 and 2022, and directly or indirectly measured children's nutrition status. The risk of bias and quality of the articles were assessed using the Joanna Briggs Institute critical appraisal tool.
RESULTS: Three types of FSMPs were identified as treatment for children with malnutrition. Ready-to-use supplementary foods improved child growth in terms of weight gain. Ready-to-use therapeutic foods mostly resulted in higher recovery rates. Oral nutrition supplements yielded significant increases in body weight and height. However, the economic value of administering FSMPs on children with malnutrition was not determined because of data scarcity.
CONCLUSION: FSMP provision to treat malnutrition in children resulted in better growth outcomes. However, further studies are needed to measure the health and economic effects of FSMPs.
METHODS: We evaluated all glioma patients who underwent treatment at the University of Malaya Medical Centre (UMMC) between 2008 and 2020. Demographic and clinical data of seizures and pattern of ASM administration in comparison to overall survival were analyzed.
RESULTS: A total of 235 patients were studied, with a minimum of one year clinical follow-up post-treatment. The median survival for low-grade glioma was 38 months whereas high-grade glioma was 15 months. One-third of our glioma patients (n = 74) presented with seizures. All patients with seizures and a further 31% of patients without seizures were started on anti-seizure medication preoperatively. Seizure and Levetiracetam (LEV) were significantly associated with OS on univariate analysis. However, only LEV (HR 0.49; 95% CI 0.23-0.87; p=0.02) was significantly associated with improving overall survival (OS) on multivariate analysis. Once ASM was adjusted for relevant factors and each other, LEV was associated with improved survival in all grade gliomas (HR 0.52; 95% CI 0.31-0.88; p=0.02) and specifically high-grade gliomas (HR 0.53; 95% CI 0.30-0.94; p=0.03).
CONCLUSIONS: Pre-operative seizures among patients with glioma indicated a better overall prognosis. The administration of ASM, specifically LEV was associated with a significant survival advantage in our retrospective cohort of patients.
METHOD: In pursuit of potential anti-inflammatory agents, a new series based on α-naphthalene acetic acid has been synthesized through multi step reactions process. 1H-NMR and 13C-NMR spectroscopic techniques were used to confirm the structures of these derivatives.
RESULTS: These compounds have been assessed for their in vitro COX-2 inhibitory activity, among them, compounds (4, 5, 13, and 3) exhibited excellent activity with IC50 value ranging from (IC50 = 0.36 ± 0.22 µM) to (IC50 = 0.43 ± 0.60 µM), while compounds (12, 11, and 14) showed significant activity.
DISCUSSION: The molecular docking and density functional theory (DFT) analyses exposed that hydrazide derivatives based on α-naphthylene acetic acid displayed strong binding affinity for COX-2. Compound 13 revealed the highest binding energy of -9.771 kJ mol-1 and the lowest IC50 (0.43 µM) over π-π interactions and multiple hydrogen bonds. DFT study exposed that compound 13 influenced the highest softening and the smallest HOMO-LUMO energy gap, representing improved reactivity.
CONCLUSION: In general, the computational as well as experimental consequences specify that compound 13 is a potent COX-2 inhibitor.
OBJECTIVE: The main objective of this systematic review is to synthesize existing evidence on the odds or risk of developing cataracts in adults with underlying CVD.
METHODS: This systematic review will adhere to the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols). Using the population, exposure, comparator, and outcome framework, this review will identify the association between established CVD and the risk of cataract development or needing cataract surgery. Systematic literature searches will be conducted in PubMed, Scopus, Web of Science, and Embase using MeSH terms from database inception to December 31, 2024. Original research articles involving adults (aged ≥18 years) that assess the statistical relationship between CVD and cataracts will be included. Two independent reviewers will screen studies, extract data, and appraise the studies' quality using the Newcastle-Ottawa Scale. If deemed feasible, meta-analyses will be conducted using random-effects models to calculate pooled effect estimates, with heterogeneity assessed using the I2 statistic.
RESULTS: This study did not receive any external funding. The literature search, study screening, and data extraction will be conducted in 2026, and data analysis will be performed accordingly. The findings are anticipated to be published in 2027.
CONCLUSIONS: This systematic review will provide a consolidated and up-to-date evaluation of the relationship between CVD and cataracts. The findings will highlight the potential importance of integrating cardiovascular risk assessment into routine ophthalmologic care. Continued refinement of study methodologies and standardization of outcome measures may be needed to address observed heterogeneity and strengthen future evidence, ultimately supporting more holistic management of patients with coexisting cardiovascular and ocular conditions.
METHODS: The AG129 mice were fed orally with FCPLJ for 3 consecutive days after 24 h of dengue virus inoculation. Plasma cytokines were screened by using ProcartaPlex immunoassay. The gene expression in the liver was analyzed by using RT2 Profiler PCR Array.
RESULTS: The results showed that FCPLJ treatment has increased the plasma CCL2/MCP-1 level during peak of viremia. Gene expression study has identified 8 inflammatory cytokine genes which were downregulated in the liver of infected AG129 mice treated with FCPLJ. The downregulated inflammatory cytokine genes were CCL6/MRP-1, CCL8/MCP-2, CCL12/MCP-5, CCL17/TARC, IL1R1, IL1RN/IL1Ra, NAMPT/PBEF1 and PF4/CXCL4.
CONCLUSION: The findings indicated the possible immunomodulatory role of FCPLJ during dengue virus infection in AG129 mice.
CASES: In Malaysia, until end of February 2020, there were four COVID-19 paediatric cases with ages ranging from 20 months to 11 years. All four cases were likely to have contracted the virus in China. The children had no symptoms or mild flu-like illness. The cases were managed symptomatically. None required antiviral therapy.
DISCUSSION: There were 2 major issues regarding the care of infected children. Firstly, the quarantine of an infected child with a parent who tested negative was an ethical dilemma. Secondly, oropharyngeal and nasal swabs in children were at risk of false negative results. These issues have implications for infection control. Consequently, there is a need for clearer guidelines for child quarantine and testing methods in the management of COVID-19 in children.